An international team led by scientists from the Wellcome Trust Sanger Institute and the University of Cambridge has managed to derive induced pluripotent stem (iPS) cells from a patient with a deficiency in enzyme alpha-1-antitrypsin, which leads to both lung emphysema and liver cirrhosis.